Possible involvement of a dopaminergic link in the analgesic action of morphine

  • G. B. Singh
  • J. N. Sharmat
  • B. N. Dhawan
Chapter

Abstract

Many workers have attempted to assign specific functions to catecholamines in the central nervous system, since Vogt (1954) demonstrated their presence in different areas of brain. Vedernikov and Afrikanov (1969) have reported that pretreatment with reserpine reduced the analgesic activity of morphine. Subsequently Vedernikov (1970) observed that prior administration of pyro­gallol, cocaine and iproniazid also potentiated the analgesic activity of morphine. On the basis of these observations noradrenaline (NA) has been suggested as playing a significant role in the analgesic activity of morphine. The possibility of NA being a neurotransmitter at the spinothalamic pathways which transmit nociceptive impulses has also been postulated. Even though in most of these experiments there is also a change in dopamine (DA) levels in the same direction, these workers have not attached much significance to changes in DA level. Recently however, DA has also been increasingly considered to have important functions at subcortical structures such as striatum and substantia nigra. In these areas, its presence in the presynaptic nerve endings has been demonstrated by histochemical methods (Dahlström and Fuxe, 1964). The involvement of dopaminergic mechanisms in morphine analgesia has recently been suggested by some workers (Calcutt, Doggett and Spencer, 1971; Carroll and Sharp 1972). The present study was undertaken to further investigate the possible role of DA in the antinociceptive (analgesic) activity of morphine.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bhargava, H. N. and Way, E. L. (1974). ‘Effect of 1-phenyl-3-(2-thiazolyl)-2-thiourea, a dopamine -ß-hydroxylase inhibitor on morphine analgesia, tolerance and physical dependence’, J. Pharmac. exp. Ther., 190, 165–175Google Scholar
  2. Calcutt, C. R., Doggett, N. S. and Spencer, P. S. J. (1971). ‘Modification of the anti-nociceptive activity of morphine by centrally administered ouabain and dopamine’, Psychopharmacologia (Berl.), 21, 111–117CrossRefGoogle Scholar
  3. Carroll, B. J. and Sharp, P. T. (1972). ‘Monoamine mediation of morphine-induced activation of mice’, Br. J. Pharmac., 76, 124–139CrossRefGoogle Scholar
  4. Dahlström, A. and Fuxe, K. (1964). ‘Evidence for the existence of monoamine containing neurones in the central nervous system. I Demonstration of monoamines in the cell bodies of brain stem neurones’, Acta physiol. scand. 232, 1–55Google Scholar
  5. Dhawan, B. N. and Gupta, G. P. (1959). ‘LSD-25 antagonism of morphine analgesia’, Archs int. Pharmacodyn. Ther., 128, 132–139Google Scholar
  6. Doggett, N. S., Spencer, P. S. J. and Turner T. A. R. (1970). ‘The pharmacological effects of ouabain administered intracerebrally to conscious mice’, Br. J. Pharmac., 40, 138–139 PGoogle Scholar
  7. Feltz, P., Krauthamer, G. and Albe-Fessard, D. (1967). ‘Neurons of the medial diencephalen. I. somato-sensory responses and caudate inhibition’, J. Neurophysiol., 30, 55–80Google Scholar
  8. Finney, D. J. (1952). Probit Analysis, 2nd Edn, Cambridge University Press, CambridgeGoogle Scholar
  9. Florvall, L. and Corrodi, H. (1970). Dopamine-β-hydroxylase inhibitors’ Acta Pharmac. Suecia, 7, 7–22Google Scholar
  10. Krauthamer, G. M. and Albe-Fessard, D. (1964). Electrophysiologic studies of the basal ganglia and striopallidal inhibition of non-specific afferent activity’, Neurophysiologia, 2, 73–83Google Scholar
  11. Lotti, V. J. and Porter, C. C. (1970). ‘Potentiation and inhibition of some central actins oft. ( — )-dopa by decarboxylase inhibitors’, J. Pharmac. exp. Ther., 172, 406–415Google Scholar
  12. Lupina, I. Z., Kleinrokz, Z. and Smolarz, J. (1971). ‘The effect of sodium diethyldithiocarbamate on the action of analgesics in albino mice’, Diss. Pharm. Pharmac., 23, 33–39CrossRefGoogle Scholar
  13. Saarnivaara, L. (1969). ‘Analgesic activity of some sympathetic drugs and their effect on morphine analgesia in rabbits’, Ann. Med., exp. Fenn., 47, 180–190Google Scholar
  14. Smith, C. B., Villareal, J. E. Bednarczyk, J. H. and Sheldon, M. I. (1970). ‘Tolerance of morphine induced increase in (14C) catecholamine synthesis in mouse brain’, Science, 170, 1106–1108PubMedCrossRefGoogle Scholar
  15. Vedernikov, Yu. P. (1970). ‘The role of brain catecholamines in morphine analgesic action in morphine tolerant rats’, J. Pharm. Pharmac., 22, 238–239CrossRefGoogle Scholar
  16. Vedernikov, Yu. P. and Afrikanov, I. I. (1969). ‘On the role of central adrenergic mechanism in morphine analgesic action’, J. Pharm. Pharmac., 21, 845–847CrossRefGoogle Scholar
  17. Vogt, M. (1954). ‘The concentration of sympathin in different parts of the central nervous system under normal conditions and after the administration of drugs’, J. Physiol., Land., 123, 451–481CrossRefGoogle Scholar
  18. Way, E. L., Loh, H. H. and Shen, F. (1968). Morphine tolerance, physical dependence and synthesis of brain 5-hydroxytryptamine’, Science, 162, 1290–1292PubMedCrossRefGoogle Scholar
  19. Weis, J. (1969). ‘Morphine antagonistic effect of chlordiazepoxide (Librium)’, Experientia, 25, 381PubMedCrossRefGoogle Scholar
  20. Woolfe G. And Macdonald. A. D. (1944). ‘The evaluation of analgesic action of pethidine hydrochloride (Demerol)’, J. Pharmac. exp. Ther., 80, 300–307Google Scholar

Copyright information

© The Contributors 1976

Authors and Affiliations

  • G. B. Singh
    • 2
  • J. N. Sharmat
    • 3
  • B. N. Dhawan
    • 1
  1. 1.Division of PharmacologyCentral Drug Research InstituteLucknowIndia
  2. 2.Regional Research LaboratoryJammuIndia
  3. 3.Department of Pharmacology, College of Physicians and SurgeonsColumbia UniversityNew YorkUSA

Personalised recommendations